12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IDX184: Development hold

FDA placed a clinical hold on HCV candidates IDX184 and IDX320 due to 3 serious adverse events in a Phase I drug-drug interaction study of the 2 compounds. Idenix said liver function abnormalities were detected in 3 healthy volunteers who received both IDX184, a polymerase inhibitor, and IDX320, a protease inhibitor. The company said liver function has...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >